ArticlePDF Available

Abstract and Figures

Over many centuries, treatment with sunlight or "heliotherapy" was used in the treatment of skin diseases. More than 3500 years ago, ancient Egyptian and Indian healers used the ingestion of plant extracts or seeds in addition to sunlight for treating "leucoderma". Modern phototherapy began with Nobel Prize winner Niels Finsen who developed a "chemical rays" lamp with which he treated patients with skin tuberculosis. However, it took several decades until phototherapy was introduced anew into the dermatological armamentarium. It was the development of photochemotherapy (PUVA) in 1974 that marked the beginning of a huge upsurge in photodermatology. The subsequent development of high intensity UV sources with defined spectra facilitated an optimized therapy for psoriasis and led to an expansion of indications for photo(chemo)therapy also in combination with topical and systemic agents. The introduction of extracorporeal photopheresis in 1987 for cutaneous T-cell lymphoma and of topical photodynamic therapy widely expanded the therapeutic possibilities in dermato-oncology.
Content may be subject to copyright.
Photochemical &
Photobiological Sciences
Cite this: Photochem. Photobiol. Sci., 2013,
Received 25th April 2012,
Accepted 24th May 2012
DOI: 10.1039/c2pp25120e
History of phototherapy in dermatology
Herbert Hönigsmann
Over many centuries, treatment with sunlight or heliotherapy was used in the treatment of skin
diseases. More than 3500 years ago, ancient Egyptian and Indian healers used the ingestion of plant
extracts or seeds in addition to sunlight for treating leucoderma. Modern phototherapy began with
Nobel Prize winner Niels Finsen who developed a chemical rays lamp with which he treated patients
with skin tuberculosis. However, it took several decades until phototherapy was introduced anew into
the dermatological armamentarium. It was the development of photochemotherapy (PUVA) in 1974 that
marked the beginning of a huge upsurge in photodermatology. The subsequent development of high
intensity UV sources with dened spectra facilitated an optimized therapy for psoriasis and led to an
expansion of indications for photo(chemo)therapy also in combination with topical and systemic agents.
The introduction of extracorporeal photopheresis in 1987 for cutaneous T-cell lymphoma and of topical
photodynamic therapy widely expanded the therapeutic possibilities in dermato-oncology.
Ancient history
Over many centuries, treatment with sunlight or heliotherapy
was used in the treatment of skin diseases. One form, more
than 3500 years ago, consisted of ingestion of a boiled extract
derived from a weed growing in the Nile Delta, Ammi majus
L. followed by exposure to the Egyptian sun for the treatment
of vitiligo (mentioned in the Papyrus Ebers), which was mista-
kenly thought to be leprosy. Independent of the Egyptian
invention, the Atharva-Veda in India reported about healers
who used a treatment consisting of ingestion of seeds of the
Bavachee plant (Psoralea corylifolia) and sunlight for treating
leucoderma. Around 1100 AD the Arab physician Ibn al-Bitar
in his book Mofradat El-Adwiya mentioned a remedy for
vitiligo with oral extracts from Ammi majus and sunlight. These
crude treatments were the very earliest form of what is now
called PUVA photochemotherapy, a treatment for psoriasis,
vitiligo and other diseases and that uses the same chemical,
psoralen, derived from the same plant source, Ammi majus
L. and followed by exposure to specially designed computer-
ized UVA units. Herodotus in 525 BC reporting on heliotherapy
correlated the strength of the human skull to the degree of
sun exposure (Herodotus, The Histories: I noticed that the
skulls of the Persians are so thin that the merest touch with a
pebble will pierce them, but those of the Egyptians on the other
hand [are] so tough that it is hardly possible to break them with a
stone. I was toldthat the reason was that the Egyptians shave
their heads from childhood, so that the bone of the skull is indu-
rated by the sun.) In the Middle Ages followed the dark
period of phototherapy.
Modern phototherapy
In the 19th century, observations were made that sunlight may
be beneficial for medical purposes. In 1877 Downes and Blunt
showed that sunlight exerts a bactericidal action and could kill
anthrax bacilli.
In 1890 Palm from Edinburgh suggested that
the sun could play a therapeutic role in rickets.
However, real modern phototherapy began with Niels
Ryberg Finsen, the father of ultraviolet therapy. In 1896,
Finsen, aware of the bacteria-destroying eects of sunlight,
developed a chemical rays lamp with which he treated a
friend who had lupus vulgaris; within a few months the
lesions were completely resolved
(Fig. 1). Finsen then
assembled a focusable carbon-arc torch. With this Finsen
Lamp he treated over 800 patients with lupus vulgaris in his
Phototherapy Institute in Copenhagen (Fig. 2). In total, 80%
were cured.
At a time when no antibiotics or anti-inflamma-
tory drugs were available, Finsens phototherapy was a major
breakthrough. In 1903, Finsen was awarded the Nobel Prize in
medicine in recognition of treatment of lupus vulgaris, with
concentrated light rays. So far, the only Nobel Prize ever
awarded for dermatology or photomedicine.
he was too ill to travel to Stockholm to receive this Prize.
Treatment of lupus vulgaris was not the only example of the
use of phototherapy in dermatology. In 1923, William Henry
Goeckerman introduced his regime (artificial broadband UVB
This article is published as part of a themed issue on current topics in
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Tel: +43-1-40400-7702; Fax: +43-1-40400-7699;
16 | Photochem. Photobiol. Sci., 2013, 12,1621 This journal is © The Royal Society of Chemistry and Owner Societies 2013
from a high pressure mercury lamp plus topical coal tar) for
psoriasis. In 1925 he published his first results
(Fig. 3). This
treatment became very popular, particularly in the U.S.A, and
was used for decades to treat psoriasis. In 1953, John Ingram,
in the United Kingdom, combined this treatment with anthra-
Surprisingly, Goeckermans or Ingrams regimens have
never been popular in central Europe.
Subsequently, it was found that broadband UVB on its own,
given in slightly erythematous doses, could clear mild forms of
psoriasis, mainly seborrheic and guttate psoriasis (see below).
By the beginning of the 1960s, Wiskemann in Hamburg,
Germany, had constructed a phototherapy system with Osram
Ultravitalux lamps and another with fluorescent UVB tubes.
Photochemotherapy and phototherapy
The revival of photochemotherapy started in 1947 when the
active ingredients of Ammi majus, 8-methoxypsoralen (8-MOP)
and 5-methoxypsoralen (5-MOP) were isolated
(Fig. 4), and
the first trials with 8-MOP and sun exposure were performed
in vitiligo patients by El-Mofty in Egypt.
Later studies used
topical 8-MOP in combination with UV irradiation to treat
The first oral use of 8-MOP to treat psoriasis was
reported in 1967.
In 1972 Mortazawi used so-called black-
light UVA tubes in a total-body-irradiation unit with topical
8-MOP to treat psoriasis.
However, the UVA output of these
tubes was insucient when 8-MOP was administered orally.
In the 1970s, lighting engineers, photophysicists, and
dermatologists worked together to develop ultraviolet irradia-
tors emitting high intensity UVA. These UVA irradiators were
designed for oral psoralen photochemotherapy to deliver
uniform high dose UVA irradiation. The seminal publication of
Parrish, Fitzpatrick, Tanenbaum, and Pathak reported the use
of this new type of UVA tube in combination with oral 8-MOP
in the treatment of psoriasis.
This approach was much more
eective than the blacklight method and represented the real
start of PUVA therapy. The term PUVA was coined by Fitzpatrick
as an acronym for psoralen and UVA (Fig. 5). The eectiveness
of PUVA was confirmed by well controlled clinical trials in
thousands of patients, both in the USA and in European
(Fig. 6). Combination therapy with oral retinoids
and PUVA contributed to greater eectiveness and long-term
safety of psoralen photochemotherapy.
The use of psoralen
baths and subsequent UVA exposure (bath PUVA) originated in
Fig. 1 Nils Ryberg Finsen (18601904) (Courtesy of the Clendening History of
Medicine Library, University of Kansas Medical Center.
Fig. 2 Lupus vulgaris treatment at the Finsen Institute in Copenhagen
(Courtesy of Prof. Hans Christian Wulf, Copenhagen).
Fig. 3 William H. Goeckerman (18841954) from:
Photochemical & Photobiological Sciences Perspective
This journal is © The Royal Society of Chemistry and Owner Societies 2013 Photochem. Photobiol. Sci., 2013, 12,1621 | 17
Scandinavia and is still in use as it avoids 8-MOP side eects
such as nausea and dizziness.
PUVA revolutionized dermatological therapy and it became
a standard treatment for many skin diseases. PUVA in fact was
the driving force in the mid-70s that sparked a whole new
series of discoveries during the next two decades i.e. newly
created high intensity ultraviolet sources such as narrowband
UVB, and later UVA1 (340400 nm).
As mentioned above, it was the development of PUVA that
led to the discovery of narrowband UVB (311313 nm)
irradiation, which replaced broadband UVB, as the first line
therapy for psoriasis due to being more ecacious. In 1976,
Parrish & Jaenicke defined the action spectrum for psoriasis
with a peak at 313 nm
(Fig. 7). However, it took almost a
decade for commercially produced artificial lamps at this wave-
length to be available as narrowband UVB. Van Weelden, Baart
de la Faille, Young and van der Leun in 1984
the clinical ecacy of narrowband UVB (Fig. 8) which was con-
firmed a few months later by Green et al.
Since then, it has
Fig. 4 Ammi Majus (Deutschlands Flora in Abbildungen (1796). From: www.
Fig. 5 Thomas B. Fitzpatrick, Edward Wigglesworth Professor of Dermatology,
(19192003) (Courtesy of Klaus Wol MD).
Fig. 6 First PUVA unit in Vienna 1975 (Courtesy of Herbert Hönigsmann MD).
Fig. 7 John A. Parrish, Professor of Dermatology emeritus (Courtesy of Herbert
Hönigsmann MD).
Perspective Photochemical & Photobiological Sciences
18 | Photochem. Photobiol. Sci., 2013, 12,1621 This journal is © The Royal Society of Chemistry and Owner Societies 2013
proven to be more eective than broadband UVB and is
increasingly used in various parts of the world. It is also ben-
eficial for a variety of other dermatoses that were previously
treated with PUVA. The use of PUVA nowadays has declined
with the emergence of narrowband UVB because of its easier
handling. Another reason may be the increased risk of skin
carcinoma after excessive exposures. Exposure to more than
350 PUVA treatments greatly increases the risk of squamous
cell carcinoma (SCC), whereas exposure to fewer than 150
PUVA treatments has, at most, modest eects on SCC risk.
far this risk has not been shown with narrowband UVB.
PUVA, however, still remained the gold standard for comparing
with other phototherapeutic modalities and serves an impor-
tant therapeutic role in cases of dermatoses recalcitrant to con-
ventional phototherapy and in dermatoses that penetrate
deeper into the skin such as plaque stage mycosis fungoides.
These eective therapiesPUVA and narrowband UVBfor
psoriasis have been a boon for the patients with generalized
psoriasis, providing ecacious ambulatory treatments
and avoiding the systemic problems of methotrexate and
In 1992, UVA1 (340400 nm) was introduced first for the
treatment of atopic dermatitis. UVA1 penetrates deeper than
UVA2 (320340 nm) and thus is able to reach deep dermal
components of the skin.
A few studies with small numbers
of patients showed ecacy in some other dermatoses such
as localized scleroderma, urticaria pigmentosa and mycosis
fungoides. The published evidence on how best to use
UVA1 has still remained limited and of variable quality. UVA1
is eective in various diseases, but appears to be the first-line
phototherapy only for some types of sclerosing diseases such
as morphea.
In the early 1980s a new form of phototherapy, namely,
extracorporeal photochemotherapy (photopheresis, ECP) was
introduced for the palliative treatment of erythrodermic
cutaneous T-cell lymphoma (CTCL).
Its ecacy was con-
firmed later by several uncontrolled clinical trials and
approved as a device in 1988 by the FDA for the treatment of
this disease. In 1994, at the International Consensus Confer-
ence on Staging and Treatment Recommendations for CTCL,
ECP was recommended as the first-line of treatment for
patients with erythrodermic CTCL.
Meanwhile, besides CTCL, ECP also plays an important role
in the treatment of chronic GVHD after allogeneic bone
marrow transplantation with excellent response rates.
addition, positive results have also been published for acute
ECP has also been used in several other autoimmune
diseases including acute allograft rejection among cardiac,
lung and renal transplant recipients and Crohns disease, with
some success.
Photodynamic therapy
At the beginning of the 20th century, the first experiments
were performed with photosensitizers and visible light in the
treatment of skin cancer, which is now known as photo-
dynamic therapy (PDT). While studying the eects of acridine
on paramecia cultures, Oscar Raab, a student of Hermann von
Tappeiner in Munich observed a toxic eect. Fortuitously,
Raab also observed that light was required for the killing of
paramecia cultures to take place.
Subsequent work in the lab-
oratory of von Tappeiner showed that oxygen was essential for
the photodynamic action”—a term coined by von Tappeiner
(Fig. 9).
Fig. 8 Jan C. van der Leun (Photo taken at the Fifth Ministerial Conference on
Environment and Development in Asia and the Pacic, 24 March 2005).
Fig. 9 Hermann Tappeiner, Edler von Tappein (18471927). © Ludwig-Maximi-
lian University, Munich.
Photochemical & Photobiological Sciences Perspective
This journal is © The Royal Society of Chemistry and Owner Societies 2013 Photochem. Photobiol. Sci., 2013, 12,1621 | 19
With the discovery of photodynamic eects, von Tappeiner
and colleagues went on to perform the first PDT trial in
patients with skin cancer using the photosensitizers eosin
and Magdala-red solution. Out of 6 patients with a facial basal
cell carcinoma treated with the dyes and exposure either to
sunlight or to arc-lamp light, 4 patients showed total tumor
resolution and a relapse-free period of 12 months
(Fig. 10).
Although they reported this success, it would take most
of the 20th century to verify the utility of photodynamic
therapies until Thomas Dougherty and co-workers at Roswell
Park Cancer Institute, Bualo NY, clinically started PDT again.
In 1978, they published impressive results in which they
treated 113 cutaneous or subcutaneous malignant tumors and
observed a total or partial resolution of 111 tumors
(Fig. 11).
The photosensitizer used in the clinical PDT trials by
Dougherty was an agent called hematoporphyrin derivative
(HpD) which was applied intravenously. However, the problem
with this route of administration was that the whole skin
became photosensitized for up to 6 weeks.
The milestone for PDT in dermatology was the observation
of Kennedy, Pottier and Pross that topically applied 5-aminole-
vulinic acid would induce tissue accumulation of protopor-
phyrin IX (PPIX) in skin tumors. PPIX acted as an endogenous
photosensitizer and upon illumination with red light destroyed
tumor tissue.
The major advantage of this regimen was that
the patients skin was sensitized only in the desired area.
Besides 5-aminolevulinic acid, methyl-aminolevulinate
(MAL) produced commercially under the name Metvix® is now
quite commonly used with similar success. PDT has become a
routine treatment for widespread actinic keratosis, superficial
basal cell carcinoma and Bowens disease.
New sensitizers
are now tested for other dermatological conditions such as
psoriasis, however no major breakthrough has been reported
so far.
The successful use of the new ultraviolet and light tech-
niques for the treatment of disease was a stimulus for the
development of a new sub-specialty called photodermatology,
which encompasses all of the applications of the diagnosis
and treatment of light-induced disorders as well as the use of
the new modalities for therapy of diseases. There now exists
both national and international Photomedicine Societies as
well as specialized journals of photodermatology. According to
a quote by Kendric C. Smith,
one of the founding fathers of
the American Society for Photobiology, I would like to close:
PhotodermatologyThe Future is Bright.
1 M. A. Pathak and T. B. Fitzpatrick, The evolution of
photochemotherapy with psoralens and UVA (PUVA): 2000
BC to 1992 AD, J. Photochem. Photobiol., B, 1992, 14,322.
2 A. H. Downes and T. P. Blunt, Researches on the eect of
light upon bacteria and other organisms, Proc. R. Soc.
London, 1877, 26, 488500.
3 T. A. Palm, The geographical distribution and aetiology of
rickets. The Practitioner, October and November, 1890.
4 N. R. Finsen, Om Lysets Indvirkninger paa Huden [On the
eects of light on the skin], Hospitalstidende, 1893, 36,
5 N. R. Finsen, Om Anvendelse i Medicinen af koncentrerede
kemiske Lysstraaler. [On the application in medicine of concen-
trated chemical rays of light] , Gyldendalske Boghandels
Forlag, Copenhagen, 1896.
6 N. R. Finsen and H. Forchhammer, Resultate der
Lichtbehandlung bei unseren ersten 800 Fällen von Lupus
vulgaris. [Results of light therapy in our first 800 cases of
lupus vulgaris], Mitt. Fins. Med. Lichtinst., 1904, 5/6,148.
7 R. Roelandts, A new light on Niels Finsen, a century after
his nobel prize, Photodermatol., Photoimmunol. Photomed.,
2005, 21, 115117.
8 W. H. Goeckerman, Treatment of psoriasis, Northwest Med.,
1925, 24, 229231.
9 J. T. Ingram, The approach to psoriasis, Br. Med. J., 1953,
12(2), 591594.
Fig. 10 Patient with rodent ulcer treated by Jesionek & Tappeiner (a) before,
and (b) after PDT with topical 5% Magdala-red solution and sun exposure.
From: Dtsch. Arch. Klin. Med., 1905, 82, 223226.
Fig. 11 Thomas J. Dougher ty, Professor of Oncology emeritus, Roswell Park
Cancer Institute. From:
Perspective Photochemical & Photobiological Sciences
20 | Photochem. Photobiol. Sci., 2013, 12,1621 This journal is © The Royal Society of Chemistry and Owner Societies 2013
10 A. Wiskemann, Die neuere Entwicklung der Lichttherapie.
[Recent developments in light therapy], Dermatol.
Wochenschr., 1963, 20(147), 377383.
11 I. R. Fahmy, H. Abu-Shady and A. A. Schönberg, Crystalline
principle from Ammi majus L., Nature, 1947, 160(4066), 468.
12 I. R. Fahmy and H. Abu-Shady, Ammi majus Linn: The iso-
lation and properties of ammoidin, ammidin and majudin,
and their eect in the treatment of leukoderma,
Q. J. Pharm. Pharmacol., 1948, 21(4), 499503.
13 A. M. El-Mofty, A preliminary clinical report on the treat-
ment of leukoderma with Ammi majus Linn, J. Egypt. Med.
Assoc., 1948, 31, 651665.
14 B. Allyn, Studies on phototoxicity in man and laboratory
animals. Paper presented at the Twenty-First Annual Meeting
of the American Academy of Dermatology, Chicago, December
15 L. Oddoze, P. Témime, J. P. Marchand and M. Benne, Las-
sociation meladinine per os et rayons U.V. dans le traite-
ment du psoriasis. [Combined oral meladinine and
ultraviolet rays in the treatment of psoriasis], Bull. Soc. Fr.
Dermatol. Syphiligr., 1967, 74(5), 609610.
16 S. M. Mortazawi, Meladinine und UVA bei Vitiligo,
Psoriasis, Parapsoriasis und Akne vulgaris. [Meladinine
and UVA in vitiligo, psoriasis, parapsoriasis and acne
vulgaris], Dermatol. Monatsschr., 1972, 158, 908909.
17 J. A. Parrish, T. B. Fitzpatrick, L. Tanenbaum and
M. A. Pathak, Photochemotherapy of psoriasis with oral
methoxsalen and longwave ultraviolet light,
N. Engl. J. Med., 1974, 291(23), 12071211.
18 K. W. Wol, T. B. Fitzpatrick, J. A. Parrish, F. Gschnait,
B. Gilchrest, H. Hönigsmann, M. A. Pathak and
L. Tanenbaum, Photochemotherapy for psoriasis with
orally administered methoxsalen, Arch. Dermatol., 1976,
112(7), 943950.
19 H. Hönigsmann and K. Wol, Results of therapy for
psoriasis using retinoid and photochemotherapy (RePUVA),
Pharmacol. Ther., 1989, 40(1), 67
20 T. Fischer and J. Alsins, Treatment of psoriasis with
trioxsalen baths and dysprosium lamps, Acta Derm.
Venereol., 1976, 56(5), 383390.
21 J. A. Parrish and K. F. Jaenicke, Action spectrum for
phototherapy of psoriasis, J. Invest. Dermatol., 1981, 76(5),
22 H. van Weelden, H. Baart de la Faille, E. Young and
J. C. van der Leun, A new development in UVB photo-
therapy of psoriasis, Br. J. Dermatol., 1988, 119(1), 119.
23 C. Green, J. Ferguson, T. Lakshmipathi and B. E. Johnson,
311 nm UVB phototherapy an eective treatment for
psoriasis, Br. J. Dermatol., 1988, 119(6), 691696.
24 R. S. Stern, PUVA follow-up study. The risk of squamous
cell and basal cell cancer associated with psoralen and
ultraviolet A therapy: a 30-year prospective study, J. Am.
Acad. Dermatol., 2012, 66(4), 553562.
25 R. M. Hearn, A. C. Kerr, K. F. Rahim, J. Ferguson and
R. S. Dawe, Incidence of skin cancers in 3867 patients
treated with narrow-band ultraviolet B phototherapy,
Br. J. Dermatol., 2008, 159(4), 931935.
26 J. Krutmann, W. Czech, T. Diepgen, R. Niedner, A. Kapp
and E. Schöpf, High-dose UVA1 therapy in the treatment of
patients with atopic dermatitis, J. Am. Acad. Dermatol.,
1992, 26(2 Pt 1), 225230.
27 E. B. Kroft, N. J. Berkhof, P. C. van de Kerkhof,
R. M. Gerritsen and E. M. de Jong, Ultraviolet A photo-
therapy for sclerotic skin diseases: a systematic review,
J. Am. Acad. Dermatol., 2008, 59(6), 10171030.
28 R. Edelson, C. Berger and F. Gasparro, et al., Treatment of
cutaneous T-cell lymphoma by extracorporeal photochemo-
therapy. Preliminary results, N. Engl. J. Med., 1987, 316,
29 F. Trautinger, R. Knobler and R. Willemze, et al., EORTC
consensus recommendations for the treatment of mycosis
fungoides/Sézary syndrome, Eur. J. Cancer, 2006, 42, 1014
30 H. T. Greinix, B. Volc-Platzer and W. Rabitsch,
et al.,
Successful use of extracorporeal photochemotherapy in the
treatment of severe acute and chronic graft-versus-host
disease, Blood, 1998, 92, 30983104.
31 H. T. Greinix, R. M. Knobler and N. Worel, et al., The eect
of intensified extracorporeal photochemotherapy on long-
term survival in patients with severe acute graft versus-host
disease, Haematologica, 2006, 91, 405408.
32 R. DallAmico and L. Murer, Extracorporeal photo-
chemotherapy: a new therapeutic approach for allograft
rejection, Transfus. Apheresis Sci., 2002, 26, 197204.
33 O. Raab, Über die Wirkung Fluorescierenden Stoe auf
Infusorien. [On the efect of fluorescent substances on
infusoria], Z. Biol., 1904, 39, 524546.
34 H. von Tappeiner and A. Jodlbauer, Über die Wirkung der
photodynamischen (fluorescierenden) Stoe auf Protozoen
und Enzyme. [On the eect of photodynamic (fluorescent)
substances on protozoa and enzymes], Dtsch. Arch. Klin.
Med., 1904, 80, 427487.
35 H. Jesionek and H. von Tappeiner, Zur Behandlung der
Hautcarcinome mit fluoreszierenden Stoen. [On the treat-
ment of skin carcinomas with fluorescent substances],
Dtsch. Arch. Klin. Med., 1905, 82, 223226.
36 T. J. Dougherty, J. E. Kaufman, A. Goldfarb,
K. R. Weishaupt, D. Boyle and A. Mittleman, Photoradia-
tion therapy for the treatment of malignant tumors, Cancer
Res., 1978, 38(8), 26282635.
37 J. C. Kennedy, R. H. Pottier and D. C. Pross, Photodynamic
therapy with endogenous protoporphyrin IX: basic prin-
ciples and present clinical experience, J. Photochem. Photo-
biol., B, 1990, 6, 143148.
38 P. Babilas, S. Karrer, A. Sidoro, M. Landthaler and
R. M. Szeimies, Photodynamic therapy in dermatologyan
update, Photodermatol., Photoimmunol. Photomed.
, 2005,
21(3), 142149.
39 K. C. Smith, Photobiology and photomedicine: the future is
bright, J. Invest. Dermatol., 1981, 77(1), 27.
Photochemical & Photobiological Sciences Perspective
This journal is © The Royal Society of Chemistry and Owner Societies 2013 Photochem. Photobiol. Sci., 2013, 12,1621 | 21
... Heliotherapy has been a therapeutic method used in the treatment of various medical conditions for >3,500 years (1). At the beginning of the 20th century, this method was considered to be revolutionary in the treatment of pulmonary tuberculosis, arthritis and small pox, the first dermatological indication being lupus vulgaris (cutaneous tuberculosis) (1). ...
... Heliotherapy has been a therapeutic method used in the treatment of various medical conditions for >3,500 years (1). At the beginning of the 20th century, this method was considered to be revolutionary in the treatment of pulmonary tuberculosis, arthritis and small pox, the first dermatological indication being lupus vulgaris (cutaneous tuberculosis) (1). The evolution of modern phototherapy has led to an improved understanding of the ultraviolet (UV) radiation effects. ...
Full-text available
Since the introduction of modern phototherapy in 1903 by Nobel Prize-winner Niels Ryberg Finsen, the usage of this therapy in the medical field has grown, techniques have been refined and developed, and it has gained widespread acceptance. Psoriasis vulgaris, parapsoriasis, lichen planus, atopic dermatitis, neonatal jaundice, urticaria, morphea, vitiligo, granuloma annulare and cutaneous T cell lymphoma are only a few dermatological indications that come along with satisfactory results. Most often, it is a 2nd or 3rd line therapy being an alternative in more severe or refractory diseases. Despite the side effects that may occur after phototherapy, which are often minor, the benefits can be significant. Unfortunately, the absolute contraindications limit the use of this type of treatment and implicitly the management of these patients. The current review aimed to combine the recommendations of phototherapy in dermatology, the types of phototherapy that can be suitable for certain dermatological diseases and to emphasize its importance in certain conditions that are associated with significant remission rates.
... The principle was applied to photoinduced tumor cell death by von Tappeiner shortly after [22]. Historical perspectives on antimicrobial PDI (sometimes also termed antimicrobial photodynamic therapy, aPDT) and the related photodynamic therapy of cancer (usually referred to as PDT) are available in the literature [23][24][25]. Although different acronyms are found in the literature, we will consistently use the term antimicrobial PDI in this review, when referring to the light induced photoinactivation of microorganisms treated with exogenous PS molecules. ...
Full-text available
The current viral pandemic has highlighted the compelling need for effective and versatile treatments, that can be quickly tuned to tackle new threats, and are robust against mutations. Development of such treatments is made even more urgent in view of the decreasing effectiveness of current antibiotics, that makes microbial infections the next emerging global threat. Photodynamic effect is one such method. It relies on physical processes proceeding from excited states of particular organic molecules, called photosensitizers, generated upon absorption of visible or near infrared light. The excited states of these molecules, tailored to undergo efficient intersystem crossing, interact with molecular oxygen and generate short lived reactive oxygen species (ROS), mostly singlet oxygen. These species are highly cytotoxic through non-specific oxidation reactions and constitute the basis of the treatment. In spite of the apparent simplicity of the principle, the method still has to face important challenges. For instance, the short lifetime of ROS means that the photosensitizer must reach the target within a few tens nanometers, which requires proper molecular engineering at the nanoscale level. Photoactive nanostructures thus engineered should ideally comprise a functionality that turns the system into a theranostic means, for instance, through introduction of fluorophores suitable for nanoscopy. We discuss the principles of the method and the current molecular strategies that have been and still are being explored in antimicrobial and antiviral photodynamic treatment.
... The use of sunlight exposure to treat various diseases such as skin diseases, diabetic ulcers, and epithelioma has been traced back to 3000 B.C. [1,2]. The modern use of light in a medical treatment known as phototherapy is producing a successful result in cancer treatment. ...
Full-text available
Photodynamic therapy (PDT) is currently enjoying considerable attention as the subject of experimental research to treat resistant cancers. The preferential accumulation of a non-toxic photosensitizer (PS) in different cellular organelles that causes oxidative damage by combining light and molecular oxygen leads to selective cell killing. However, one major setback, common among other treatment approaches, is tumor relapse and the development of resistance causing treatment failure. PDT-mediated resistance could result from increased drug efflux and decreased localization of PS, reduced light exposure, increased DNA damage repair, and altered expression of survival genes. This review highlights the essential insights of PDT reports in which PDT resistance was observed and which identified some of the molecular effectors that facilitate the development of PDT resistance. We also discuss different perceptions of PDT and how its current limitations can be overturned to design improved cancer resistant treatments.
The emergence of antibiotic-resistant bacterial strains is seriously endangering the global healthcare system. There is an urgent need for combining imaging with therapies to realize the real-time monitoring of pathological condition and treatment progress. It also provides guidance on exploring new medicines and enhance treatment strategies to overcome the antibiotic resistance of existing conventional antibiotics. In this review, we provide a thorough overview of the most advanced image-guided approaches for bacterial diagnosis (e.g., computed tomography imaging, magnetic resonance imaging, photoacoustic imaging, ultrasound imaging, fluorescence imaging, positron emission tomography, single photon emission computed tomography imaging, and multiple imaging), and therapies (e.g., photothermal therapy, photodynamic therapy, chemodynamic therapy, sonodynamic therapy, immunotherapy, and multiple therapies). This review focuses on how to design and fabricate photo-responsive materials for improved image-guided bacterial theranostics applications. We present a potential application of different image-guided modalities for both bacterial diagnosis and therapies with representative examples. Finally, we highlighted the current challenges and future perspectives image-guided approaches for future clinical translation of nano-theranostics in bacterial infections therapies. We envision that this review will provide for future development in image-guided systems for bacterial theranostics applications.
Human urothelial bladder carcinoma (uBC) is the second most tumor entity of the urogenital tract. As far as possible, therapy for non-muscle invasive uBC takes place as resection of the tumor tissue, followed by intravesical chemotherapy or immunotherapy. Because of the high recurrence rate of uBC, there is a need for improved efficiency in the treatment. In the present in vitro study we have evaluated a new approach to enhance the cytotoxic efficiency of Mitomycin C (MMC), which is commonly used for intravesical treatment of uBC on the relevant urothelial cancer cell line RT112. For that we used quasi-monochromatic blue light (453 ± 10 nm) at its non-toxic dose of 110 J/cm² as an additive stimulus to enhance the therapeutic efficiency of MMC (10 μg/ml). We found, that blue light exposure of RT112 cells led to a very strong increase in intracellular production of reactive oxygen species (ROS) and to a significant reduction (p < 0.05) of all function parameters of mitochondrial respiration, including basal activity and ATP production. Although not being toxic when used as a single impact, together with MMC blue light strongly enhanced the therapeutic efficiency of MMC in the form of significantly enhanced cytotoxicity via apoptosis and secondary necrosis. Our results clearly show that blue light, most likely due to its ability to increase intracellular ROS production and reduce mitochondrial respiration, increased the cytotoxic efficiency of MMC and therefore might represent an effective, low-side-effect, and success-enhancing therapy option in the local treatment of bladder cancer.
Since they were first synthesized in 1965 by Treibs and Jacob, squaraine dyes have revolutionized the polymethine dyes' ‘universe’ and their potential applications due to their indisputable physical, chemical and biological properties. After 30 years and up to the present, various research teams have dedicated themselves to studying the squaraines' photodynamic therapy application using in vitro and in vivo models. The various structural modifications made to these compounds, as well as the influence they have shown to have in their phototherapeutic activity, are the main focus of the present review. Finally, the most evident limitations of this class of dyes, as well as future perspectives in the sense of hypothetically successfully overcoming them, are suggested by the authors.
Full-text available
Full-text available
Phototherapy is the use of sun light or light from other sources for therapeutic purposes. It is conventionally used for treating several medical conditions like Psoriasis, Vitiligo, Atopic dermatitis, Lichen planus, Alopecia areata, Urticaria pigmentosa, Acne vulgaris and Neonatal jaundice etc. It involves the use of fluorescent light bulb, sunlight and light emitting diodes to treat above mentioned medical conditions. The phototherapy is being used since time unknown to treat different diseases but in modern era different techniques like PUVA, electric light bulb and electric generators and various other light sources are also being used. And it's gaining more importance in treating dermatologic disorders with non-infectious etiology. William Henry Goeckerman use phototherapy to treat Psoriasis in 1923. The phototherapy is not only suggested by modern physicians but also used by unani physicians for the purpose of treating different diseases. In this paper we are trying to explore some disease conditions in which phototherapy is being used for treatment purpose successfully.
Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell–mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. We present 21 patients (10 men and 11 women) with hematological malignancies with a median age of 36 years (range, 25 to 55 years) who had received marrow grafts from sibling (n = 12) or unrelated (n = 9) donors. Six patients had acute graft-versus-host disease (GVHD) grade II to III not responding to cyclosporine A (CSA) and prednisolone when referred to extracorporeal photochemotherapy (ECP). In 15 patients, 2 to 24 months after bone marrow transplantation (BMT), extensive chronic GVHD with involvement of skin (n = 15), liver (n = 10), oral mucosa (n = 11), ocular glands (n = 6), and thrombocytopenia (n = 3) developed and was unresponsive to conventional therapy, including steroids. All patients were treated with ECP on 2 consecutive days every 2 weeks for the first 3 months and thereafter every 4 weeks until resolution of GVHD. ECP was tolerated excellently without any significant side effects. After a median of 14 cycles of ECP, acute GVHD resolved completely in 4 of 6 patients (67%) and partially in another 2 patients. Cutaneous chronic GVHD completely resolved in 12 of 15 (80%) patients. Contractures of knees and elbows due to scleroderma resolved partially. Oral mucosal ulcerations resolved in all patients. Seven of 10 patients (70%) with liver involvement had complete responses after ECP. After discontinuation of ECP, no severe infections were observed. Our findings suggest that ECP is a safe and effective adjunct therapy for both acute and extensive chronic GVHD with skin and visceral involvement and resistance to conventional therapy. © 1998 by The American Society of Hematology.
• Photochemotherapy denotes a therapeutic approach that is based on the interaction of light and a photoactive drug. This study describes the efficacy of photochemotherapy, using orally administered methoxsalen and long-wave ultraviolet light in 91 patients with severe, generalized psoriasis. Oral administration of methoxsalen was followed by exposure to a high-intensity long-wave ultraviolet light source, emitting a continuous spectrum between 320 and 390 nm (peak, 365 nm) and an energy of 5.6 to 7.5 mw/sq cm at 15 cm. There was complete clearing of 82 patients (90%), a 90% to 100% clearing in seven (8%), and a satisfactory improvement in two (2%). A paired comparison study in 54 patients showed photochemotherapy to be far more effective than ultraviolet light emitted by fluorescent bulbs or a xenon source. Eighty-five percent of the patients receiving outpatient maintenance treatment have remained in remission for periods up to 400 days. (Arch Dermatol 112:943-950, 1976)
In 1925, I published an article¹ on the treatment for psoriasis by an ointment of crude coal tar and ultraviolet light. This treatment has given far better results than any method I have ever used. The advantages that I claimed for this treatment were its uniform effectiveness, its lack of danger and even untoward symptoms, its nondestructive character, its accessibility and its comparative cheapness. Further experience justifies these claims, and in some respects establishes the method as being unique in its therapeutic results. DEVELOPMENT OF THE METHOD OF TREATMENT It has long been known that most patients with psoriasis are better in summer than in winter, that a sojourn in a locality with much sunshine is beneficial, and that sunbaths alone will clear up some attacks. Therefore, it was argued that if it were possible to sensitize the patches artificially, the response to light should be more